RecruitingPhase 3NCT07416474

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Sponsor

RemeGen Co., Ltd.

Enrollment

574 participants

Start Date

Apr 3, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RC148 plus Carboplatin and Paclitaxel and a drug called Tislelizumab plus Carboplatin and Paclitaxel for people with non-small cell lung cancer. The study is currently recruiting participants at 78 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRC148 plus Carboplatin and Paclitaxel

RC148, Carboplatin, Paclitaxel

DRUGTislelizumab plus Carboplatin and Paclitaxel

Tislelizumab, Carboplatin, Paclitaxel

Locations(78)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Peking University Cancer Hospital

Beijing, Beijing Municipality, China

Cancer Hospital Affiliated to Chongqing University

Chongqing, Chongqing Municipality, China

Chongqing Medical University First Affiliated Hospital

Chongqing, Chongqing Municipality, China

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Union Hospital Affiliated to Fujian Medical University

Fuzhou, Fujian, China

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

The First Affiliated Hospital of Lanzhou University

Lanzhou, Gansu, China

Dongguan People's Hospital

Dongguan, Guangdong, China

Cancer Hospital Affiliated to Guangzhou Medical University

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Sun Yat-sen University First Affiliated Hospital

Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Jiangmen Central Hospital

Jiangmen, Guangdong, China

Shenzhen People's Hospital

Shenzhen, Guangdong, China

The Fifth Affiliated Hospital of Sun Yat-sen University

Zhuhai, Guangdong, China

The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China

Cancer Hospital Affiliated to Guangxi Medical University

Nanning, Guangxi, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangzhou, China

Guizhou Provincial People's Hospital

Guiyang, Guizhou, China

The Fourth Affiliated Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Cancer Hospital Affiliated to Harbin Medical University

Harbin, Heilongjiang, China

Anyang Cancer Hospital

Anyang, Henan, China

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

Nanyang Second People's Hospital

Nanyang, Henan, China

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Henan Provincial People's Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou

Zhengzhou, Henan, China

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Hunan Cancer Hospital

Changsha, Hunan, China

Jiangsu Cancer Hospital

Nanjing, Jiangsu, China

Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China

Zhongda Hospital Affiliated to Southeast University

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Xuzhou Central Hospital

Xuzhou, Jiangsu, China

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Jilin Cancer Hospital

Changchun, Jilin, China

Liaoning Cancer Hospital

Shenyang, Liaoning, China

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

The Second Affiliated Hospital of Air Force Medical University of the Chinese People's Liberation Army

Xi'an, Shaanxi, China

Affiliated Hospital of Binzhou Medical University

Binzhou, Shandong, China

Jinan Central Hospital

Jinan, Shandong, China

Linyi Cancer Hospital

Linyi, Shandong, China

Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Shanxi Cancer Hospital

Taiyuan, Shanxi, China

Sichuan Cancer Hospital

Chengdu, Sichuan, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, China

Tianjin Chest Hospital

Tianjin, Tianjin Municipality, China

Affiliated Cancer Hospital of Xinjiang University

Ürümqi, Xinjiang, China

Yunnan Cancer Hospital

Kunming, Yunnan, China

Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Taizhou Hospital of Zhejiang Province

Taizhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Affiliated Hospital of Hebei University

Baoding, China

Peking Union Medical College Hospital

Beijing, China

The First People's Hospital of Chenzhou City

Binzhou, China

Cangzhou Central Hospital

Cangzhou, China

Xiangya Hospital of Central South University

Changsha, China

The Second Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army

Chongqing, China

Shanghai Chest Hospital

Shanghai, China

Shanghai Pulmonary Hospital

Shanghai, China

The First Hospital of Shanxi Medical University

Taiyuan, China

Tianjin Medical University General Hospital

Tianjin, China

Hubei Cancer Hospital

Wuhan, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technolo

Wuhan, China

The First Affiliated Hospital of Wannan Medical College

Wuhu, China

Zhuzhou Central Hospital

Zhuzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07416474

Related Trials

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT0718599778 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

NCT07642024

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT0755433950 locations

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT0535570140 locations